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The phosphoinositide 3-kinase (PI3K)/mammalian target of
rapamycin (mTOR) pathway is very frequently activated in human
cancer by a variety of genetic and epigenetic events. This path-
way is thought to contribute to many of the hallmarks of cancer
and a large array of agents targeting its key components are cur-
rently undergoing clinical testing in cancer patients. In addition to
rapamycin analogs (“rapalogs”), which are approved for the treat-
ment of multiple cancers, PI3K inhibitors are likely to be soon
approved for B-cell malignancies (1, 2).
In this research topic, we have assembled a collection of arti-
cles describing recent key aspects of the role of the PI3K/mTOR
pathway in cancer and the development of targeted therapies.
Martini et al. review the role of the different classes of PI3K
isoforms as targets in oncology (3). Tzenaki and Papakonstanti
focus on the role of the PI3K isoform p110δ in cancer (4). The role
of the PI3K/mTOR pathway in cell cycle progression and metab-
olism is discussed by Vadlakonda and colleagues (5–7). Pardo and
Seckl present an overview of S6K2, the p70 ribosomal S6 kinase
homolog (8).
Porta and colleagues present an up to date overview of the
development of selective inhibitors of Akt, mTOR, and PI3K with
a focus on the latest clinical trials (9). Weigelt and Downward
review the genetic determinants of response to these targeted
agents (10). Fox et al. discuss the potential of co-targeting PI3K
and the estrogen receptor (ER) in breast cancer (11).
ACKNOWLEDGMENTS
Work in the author’s laboratory is supported by grants from
the European Union FP7 (ASSET, project number: 259348 and
LUNGTARGET, project number: 259770), the Swiss National Sci-
ence Foundation (Grant 31003A-146464), the Fondation FORCE,
the Novartis Stiftung für Medizinisch-Biologische Forschung, the
Jubiläumsstiftung der Schweizerischen Mobiliar Genossenschaft,
the Stiftung zur Krebsbekämpfung, the Huggenberger-Bischoff
Stiftung zur Krebsforschung, the UniBern Forschungsstiftung, the
Stiftung für klinisch-experimentelle Tumorforschung, Bern and
the Berner Stiftung für krebskranke Kinder und Jugendliche.
REFERENCES
1. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Ide-
lalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med
(2014) 370:997–1007. doi:10.1056/NEJMoa1315226
2. Gopal AK, Kahl BS, De Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ,
et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lym-
phoma. N Engl J Med (2014) 370:1008–18. doi:10.1056/NEJMoa1314583
3. Martini M, Ciraolo E, Gulluni F, Hirsch E. Targeting PI3K in cancer: any good
news? Front Oncol (2013) 3:108. doi:10.3389/fonc.2013.00108
4. Tzenaki N, Papakonstanti EA. p110d PI3 kinase pathway: emerging roles in
cancer. Front Oncol (2013) 3:40. doi:10.3389/fonc.2013.00040
5. Vadlakonda L, Dash A, Pasupuleti M, Anil Kumar K, Reddanna P. Did we
get pasteur, warburg and crabtree on a right note? Front Oncol (2013) 3:186.
doi:10.3389/fonc.2013.00186
6. Vadlakonda L, Dash A, Pasupuleti M, Kotha AK, Reddanna P. The paradox
of Akt-mTOR interactions. Front Oncol (2013) 3:165. doi:10.3389/fonc.2013.
00165
7. Vadlakonda L, Pasupuleti M, Reddanna P. Role of PI3K-Akt-mTOR and Wnt
signaling pathways in G1-S transition of cell cycle in cancer cells. Front Oncol
(2013) 3:85. doi:10.3389/fonc.2013.00085
8. Pardo OE, Seckl MJ. S6K2: the neglected S6 kinase family member. Front Oncol
(2013) 3:191. doi:10.3389/fonc.2013.00191
9. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer.
Front Oncol (2014) 4:64. doi:10.3389/fonc.2014.00064
10. Weigelt B, Downward J. Genomic determinants of PI3K pathway inhibitor
response in cancer. Front Oncol (2012) 2:109. doi:10.3389/fonc.2012.00109
11. Fox EM, Arteaga CL, Miller TW. Abrogating endocrine resistance by targeting
ER alpha and PI3K in breast cancer. Front Oncol (2012) 2:doi:10.3389/fonc.
2012.00145
Conflict of Interest Statement: The author declares that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 19 March 2014; accepted: 05 April 2014; published online: 22 April 2014.
Citation: Arcaro A (2014) Targeting PI3K/mTOR signaling in cancer. Front. Oncol.
4:84. doi: 10.3389/fonc.2014.00084
This article was submitted to Molecular and Cellular Oncology, a section of the journal
Frontiers in Oncology.
Copyright © 2014 Arcaro. This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
www.frontiersin.org April 2014 | Volume 4 | Article 84 | 1
